Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
Christoph Saal;Clemens Kuehn;Axel Becker;Frank Stieber;Heinz Hermann Bokel;Dieter Dorsch;Cristina Donini;Oliver Schadt
发明人:
Axel Becker,Clemens Kuehn,Christoph Saal,Oliver Schadt,Dieter Dorsch,Heinz Hermann Bokel,Frank Stieber,Cristina Donini
申请号：
US13143831
公开号：
US08710058B2
申请日:
2009.12.04
申请国别(地区):
US
年份:
2014
代理人:
摘要：
Compounds of the present invention concern 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The compound, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile, has the following structural formula:The hydrochloride solvates and crystalline modifications thereof according to the invention are useful for treatment of physiological and/or pathophysiological conditions, such as cancer, that are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, especially Met-kinase. The present invention further relates to processes of manufacturing these crystalline modifications.
